Clinical Trial Update: Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria [Phase 1]

View source ↗

Summary

Phase 1b open-label study evaluating the safety, tolerability, and pharmacodynamics of EP262 in subjects with chronic inducible urticaria has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inducible Urticaria

Drugs mentioned

• EP262

Snippet

Sponsor: Escient Pharmaceuticals, Inc | Conditions: Chronic Inducible Urticaria | Phase 1 | Status: COMPLETED